// App-Quantinova.ai

[FRI0254] : PREDICTIVE VALUE OF PRETREATMENT RESISTIN LEVELS FOR EROSIVE DISEASE IN EARLY RA TREATED WITH DMARDS AND INFLIXIMAB

Researchers

Presenter

  • K. Vuolteenaho

Principal Investigators

  • H. Kautiainen

  • T. Mottonen

  • P. Hannonen

  • M. Korpela

  • M. Kauppi

  • O. Kaipiainen-Seppanen

  • R. Luosujarvi

  • R. Nieminen

  • M. Leirisalo-Repo

  • E. Moilanen

Medical Centers

  • Helsinki University Central Hospital Cancer Center, Helsinki, Finland

Locations

  • Finland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Erosive Disease

  • Inflammatory Arthritis

Biomarkers

  • Resistin

  • Estrogen receptor alpha

  • Adipokines

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • Prednisolone

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved